Uncategorized

The key to realising product and process visibility across the life sciences

Three years on, how did the pandemic transform pharmacovigilance?

The EU Commission’s proposals to revise pharmaceutical legislation is a step forward but there is more work to do

Oncology – what does it show us about the wider NHS in the years ahead?

Why commercial sponsors should continue to choose the UK when delivering clinical research

The NHS’ next chapter – managed decline, or new opportunities for pharma?

In a rapidly evolving healthcare landscape, digitisation can transform pharma’s quest to improve mental health outcomes

How do we make rare disease clinical trials more human?

Therapeutic cancer vaccines can destroy our most formidable enemy

Adapting to the new normal includes a wider understanding of the challenges in clinical trial decentralisation

From the briefing room – how to future-proof healthcare comms

Decarbonising the pharma supply chain and the journey to net zero

‘Women in Pharma’ is a new group that’s been making waves on LinkedIn. PharmaTimes caught up with the founders to discover more

The challenge of achieving functioning NHS digital change cost-effectively

Navigating the maze of NHS medicines optimisation requires a truly joined-up approach